Target the Gene
Silence the Disease
Pipeline
Drug(Disease)
Disease
Pre-clinical
Pre-IND
Phase 1
Phase 2
Phase 3
-
ARO-AAT (Alpha-1 Liver Disease)Alpha-1 Liver DiseasePartnered with Takeda
-
ARO-APOC3 (Hypertriglyceridemia)Hypertriglyceridemia
-
ARO-ANG3 (Dyslipidemia)Dyslipidemia
-
ARO-PNPLA3 (NASH)NASH
-
GSK4532990 (NASH)NASHLicensed to GlaxoSmithKline
-
ARO-C3 (Complement Mediated Disease)Complement Mediated Disease
-
ARO-ENaC2 (Cystic Fibrosis)Cystic Fibrosis
-
ARO-MUC5AC (Muco-obstructive)Muco-obstructive
-
ARO-RAGE (Inflammatory)Inflammatory
-
ARO-MMP7 (Idiopathic Pulmonary Fibrosis)Idiopathic Pulmonary Fibrosis
-
ARO-COV (COVID-19 )COVID-19
-
ARO-DUX4 (FSHD)FSHD
-
ARO-SOD1 (ALS)ALS
-
HZN-457 (Gout)GoutPartnered with Horizon
-
JNJ-3989 (Hepatitis B)Hepatitis BLicensed to Janssen
-
Olpasiran (Cardiovascular Disease)Cardiovascular DiseaseLicensed to Amgen
- Liver
- Lung
- Muscle
- CNS
Science
Arrowhead has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies.
Learn MoreAbout Arrowhead
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.
Learn More